Usana Health Sciences Inc Dossier - Source-backed chat

Usana Health Sciences Inc

USNANYSE

SectorConsumer Staples

IndustryPersonal Care Products

Beta (adjusted)0.82

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $14.47Price as of 30 Sep 2026

Data confidence Sign in to view data confidence

Market Cap $267.4M

Enterprise Value $112.8M

Shares Outstanding 18.2M diluted

Moat Rating None

Next Earnings Date21 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

USANA Health Sciences is transitioning from a single-channel direct selling model to a diversified, omnichannel health and wellness enterprise. While the company's Q1 2026 results showed strong operational execution with sequential improvements in its core nutritional business and triple-digit growth in Rise Wellness, it continues to face temporary margin pressures from restructuring, high customer acquisition costs at Hiya, and geographic tax rate headwinds. A Hold rating is warranted as the market monitors the stabilization of gross margins across its newly acquired segments and the execution of its in-house manufacturing strategy.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$25.00

Mean target$25.00

High · most bullish analyst$25.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$14.0020%

Restructuring efforts drag on longer than expected, promotional discounts continue to depress Rise Wellness margins, and regulatory scrutiny or direct-selling headwinds in China further reduce active customer counts, leading to continued net earnings erosion.

Base CaseCentral scenario

$22.0050%

USANA maintains stable consolidated net sales between $925 million and $1 billion for FY2026, with adjusted EBITDA tracking the guided range of $101 million to $109 million. Core nutritional customer counts stabilize in China, and omnichannel sales grow to represent over 20% of total net sales.

Bull CaseUpside scenario

$30.8030%

The Rise Wellness segment's nationwide Costco expansion stabilizes with gross margins recovering toward historical levels, while Hiya's transition to in-house manufacturing successfully offsets high customer acquisition costs, driving significant operating margin expansion in the second half of 2026.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong balance sheet with $163 million in cash and cash equivalents and minimal debt ($14 million).
Successful omnichannel diversification with Rise Wellness generating triple-digit sequential growth and Hiya scaling to $32 million in Q1 2026 sales.
Core nutritional business showing solid sequential improvement, particularly with 13% sequential active customer growth in Greater China.

Key Investment Risks

Temporary margin compression from promotional discounts (Rise Wellness gross margin at 7.1% in initial Costco rollout).
High customer acquisition costs (CAC) for direct-to-consumer segments due to advertising algorithm changes.
Elevated effective tax rate driven by geographic mix shifts in earnings.

Thesis Invalidation Triggers

Failure of Rise Wellness gross margins to improve toward the 12% target as Costco promotional discounts subside.
A sequential decline in Greater China active customer counts or net sales.
Inability to achieve the projected H2 cost savings from shifting Hiya manufacturing in-house.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.